Toggle Health Problems and D

A tiny amount of vitamin D does not help (Rheumatoid Arthritis in this case) – Aug 2020

The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis

Front Med (Lausanne)
. 2020 Jul 15;7:312. doi: 10.3389/fmed.2020.00312. eCollection 2020.
Jianhong Wu 1, Jianling Dong 2, Shilin Li 3, Jiaang Luo 2, Yu Zhang 2, Hong Liu 2, Yuanpiao Ni 2, Xue Li 3, Jun Zhou 3, Hang Yang 3, Qianrong Xie 3, Xuejun Jiang 1, Tingting Wang 1, Pingxi Wang 3, Fanwei Zeng 3, Yanpeng Chu 3, Jing Yang 2, Fanxin Zeng 3


From PDF: "VitD was used orally for patients and included calcitriol (0.25 to 0.5 µg/day), or calcium carbonate and vitamin D3 tablets (200 to 400 IU/day)"

Rheumatoid Arthritis category in VitaminDWiki starts with

103 RA items     See also Overview Rheumatoid Arthritis   Autoimmune  Inflammation   Pain - Chronic

    Highlights of RA studies in VitaminDWiki
RA worse if low Vitamin D

RA and Vitamin D Receptor (auto-updated)

RA Treated by Vitamin D

 Download the PDF from VitaminDWiki

Background: The aim of this study is to evaluate the clinical efficacy of vitamin D (VitD) supplementation in terms of response to treatment and improvement of disease activity in rheumatoid arthritis (RA).

Methods: This study analyzed 1180 RA patients' records treated at Mianyang Central Hospital from February 2015 to July 2019. The patients were allocated into VitD group and control group based on their medical regimens. The outcome measures were primary efficacy, defined as treatment response-based EULAR response criteria in RA, and secondary efficacy, defined as improvement in disease activity indicators. Safety was evaluated according to the incidence of all-cause infections.

Results: At month 6, the primary efficacy revealed that there were 22.8% good responders and 19.0% moderate responders in the VitD group, and 22.3% good responders and 22.3% moderate responders in the control group; there were no differences between the two groups (p = 0.754). The similar primary efficacy outcomes were observed at months 3, 12, and >12. The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12. The subgroups (based on baseline DAS28 (CRP), glucocorticoids use and disease duration) analysis results suggested that VitD group didn't have the advantage for treating RA. The incidence of infections was similar in the two groups.

Conclusion: VitD supplementation did not provide additional benefit for anti-rheumatic treatment. These data supported the need for prospective, randomized, controlled trials to evaluate the role of VitD supplementation in treating RA.

Created by admin. Last Modification: Sunday August 9, 2020 12:51:37 GMT-0000 by admin. (Version 3)

Attached files

ID Name Comment Uploaded Size Downloads
14142 RA not helped_compressed.pdf PDF 2020 admin 09 Aug, 2020 12:49 724.31 Kb 142
See any problem with this page? Report it (FINALLY WORKS)